Program
MHB009C
A development code. Also written as “MHB009C for Injection”.
Its studies are led by Minghui Pharmaceutical.
Furthest: phase 2, since Dec 22, 20251 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Minghui Pharmaceutical | 11 open or running | phase 2since Dec 22, 2025 | Dec 22, 2025 | Feb 2028phase 2 · NCT07326488 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2025First study: phase 2 study in Advanced Malignant Solid TumorFirst studyNCT07326488 · 200 planned · China
Ahead
- Feb 2028Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07326488
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07326488Advanced Malignant Solid Tumor · China | 2 | Recruiting | Feb 2028 | 200 |
How it is read
Names in the registry
- “MHB009C for Injection”, 1 entry
Codes read as this program: MHB009C.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.